Trial Profile

Evaluation of Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Patients With/Without Substitution Therapy in Austria.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Buprenorphine; Methadone; Morphine
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

22 Apr 2012 Actual patient number changed from 333 to 353 as reported by ClinicalTrials.gov.
15 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
28 Jan 2011 Planned end date changed from Nov 2010 to Mar 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com